Chemomab is a biotechnology company focused on developing proprietary monoclonal antibodies aimed at novel targets to treat immune-mediated and fibrotic disorders, including rare or 'orphan' diseases. The company operates in the biopharmaceutical sector, primarily serving patients with limited treatment options for these complex conditions. Chemomab's business model revolves around research and development (R&D) of innovative therapies, which are then patented and brought to market either independently or through partnerships with larger pharmaceutical companies. Revenue is generated through a combination of direct sales, licensing agreements, and milestone payments from collaborative partnerships. The company's lead compound, CM101, is a first-in-class monoclonal antibody that has shown compelling efficacy in preclinical and clinical studies for treating these disorders. Chemomab's strategic focus on niche markets with high unmet medical needs positions it for significant growth potential as it advances its pipeline of novel therapies.

Keywords: monoclonal antibodies, immune-mediated disorders, fibrotic disorders, orphan diseases, biotechnology, biopharmaceutical, CM101, R&D, innovative therapies, niche markets.